BOULDER, Colo., July 3 /PRNewswire/ -- Cinpathogen, a U.S.-based bioresearch firm, has partnered with the Institute of Biomedical Sciences at Fudan University in Shanghai, to form the Fudan Cinpathogen Center for Clinical and Molecular Research.
"This partnership provides an unprecedented opportunity," said Dr. Richard D. Irons, Cinpathogen's CEO. "By integrating Western and Chinese medical research systems, we can advance global biomedical research and help satisfy China's growing demand for high-quality healthcare."
The Fudan-Cinpathogen Center for Clinical and Molecular research brings together clinical operations, modern diagnostic laboratories and access to one of the largest tissue banks dedicated to diseases of the blood and immune systems in order to support diagnosis and conduct protocol-driven research on the etiology, pathogenesis and treatment of disease.
More information about Cinpathogen and the Fudan-Cinpathogen Center for Clinical and Molecular Research can be found at the website: http://www.cinpathogen.com
Cinpathogen is a bioresearch company with offices in Boulder, CO and Shanghai, China. The company has unparalleled experience conducting medical research in China that conforms to both local and international regulatory, ethical and scientific standards.
Cinpathogen reports and publications appear in many peer-reviewed scientific journals, including Leukemia Research, International Journal of Hematology, Proceedings of the American Association for Cancer Research, and Chinese Journal of Oncology.
Contact: Richard D. Irons (303) 381-2543 Email: contact@cinpathogen.comhttp://www.cinpathogen.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
CinpathogenCONTACT: Richard D. Irons of Cinpathogen, +1-303-381-2543 orcontact@cinpathogen.com
Web site: http://www.cinpathogen.com/
